CN102039007A - Therapy equipment with targeting function - Google Patents
Therapy equipment with targeting function Download PDFInfo
- Publication number
- CN102039007A CN102039007A CN 201010557946 CN201010557946A CN102039007A CN 102039007 A CN102039007 A CN 102039007A CN 201010557946 CN201010557946 CN 201010557946 CN 201010557946 A CN201010557946 A CN 201010557946A CN 102039007 A CN102039007 A CN 102039007A
- Authority
- CN
- China
- Prior art keywords
- module
- light
- targeting function
- treatment device
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008685 targeting Effects 0.000 title claims abstract description 39
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 239000013307 optical fiber Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 7
- 230000000638 stimulation Effects 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 35
- 230000006870 function Effects 0.000 claims description 31
- 230000035807 sensation Effects 0.000 claims description 29
- 230000003287 optical effect Effects 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 239000003900 neurotrophic factor Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 4
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 3
- 239000002041 carbon nanotube Substances 0.000 claims description 3
- 229910021393 carbon nanotube Inorganic materials 0.000 claims description 3
- 229910003472 fullerene Inorganic materials 0.000 claims description 3
- 229910021389 graphene Inorganic materials 0.000 claims description 3
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010034960 Photophobia Diseases 0.000 claims 1
- 208000013469 light sensitivity Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 28
- 210000004027 cell Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 230000006378 damage Effects 0.000 abstract description 9
- 210000001519 tissue Anatomy 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 17
- 210000005036 nerve Anatomy 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 4
- 210000000944 nerve tissue Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 101000903581 Natronomonas pharaonis Halorhodopsin Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 210000002945 adventitial reticular cell Anatomy 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000011540 sensing material Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000002672 stereotactic surgery Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to therapy equipment with a targeting function, comprising a central control module, a photostimulation module, optical fiber, a signal acquisition module and a slow release module, wherein the central control module controls the photostimulation module, the signal acquisition module and the slow release module; the slow release module is used for releasing a targeted photosensitive material and/or photosensitive gene; the photostimulation module generates laser and carries out photostimulation on the targeted photosensitive material and/or photosensitive gene by the optical fiber; the signal acquisition module is used for acquiring biological signals in a focus before and after photostimulation and transmitting the biological signals to the central control module; and the central control module analyzes and processes the biological signals to generate corresponding parameters and respectively controls the photostimulation module and the slow release module according to the parameters. Since the targeting photosensitive material can enter tumor cells to be excited, but not enter normal cells, the therapy equipment with the targeting function can reduce the damages to normal tissues of a patient and improves the therapy effect.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the field of medical instruments, in particular to a treatment device with a targeting function.
[ background of the invention ]
Tumors that grow intracranial are known as brain tumors and include primary brain tumors that develop from the parenchyma of the brain and secondary brain tumors that metastasize to the cranium from other parts of the body. In recent years, the incidence rate of brain tumor is on the rise, and 20-30% of other malignant tumors are finally transferred into the cranium. Once a brain tumor occupies a certain space in the cranium, whether the brain tumor is benign or malignant in nature, the intracranial pressure can be increased, brain tissues are pressed, central nerves are damaged, and the life of a patient is threatened.
The traditional treatment for central nervous system tumor mainly comprises three types of operation treatment, chemotherapy and radiation therapy. The operation treatment is to remove the tumor through surgical operation to achieve the purposes of removing tumor cells and preventing the differentiation and growth of the tumor cells, but the trauma in the operation process is large, unpredictable or irreversible results are easily caused, and serious sequelae are left for patients; the chemotherapy is a treatment mode which utilizes chemical drugs to kill tumor cells and inhibit the growth and the reproduction of the tumor cells, has treatment effects on primary focuses, metastatic focuses and the like, but can kill the tumor cells and normal cells at the same time to cause damage to patients; radiotherapy refers to the use of radiation to kill tumor cells, which is effective for many tumors, but can also cause harm to the patient.
With the progress of treatment, new treatments, such as electrochemical therapy, have been developed in recent years. Electrochemotherapy (ECT) is a method of treating tumors using stimulation of local electrical pulses. It makes the tumor locally produce a series of electrochemical reactions by direct current and current pulse, causing the change of the living environment of the tumor cells, and forcing the change of DNA, enzyme and protein conformations, finally leading to the death of the tumor cells. The method is highly destructive to in vivo or superficial tumors, has easily controlled destruction range, can selectively kill tumor cells, but may cause fever or skin reaction, and seriously causes local burn or necrosis of patients.
In summary, the traditional methods for treating tumors are all prone to cause great damage to patients, and bring adverse effects to patients.
[ summary of the invention ]
In view of the above, there is a need for a therapeutic device with a specific targeting function, which can reduce the damage to the normal tissues of the patient and improve the therapeutic effect.
A treatment device with a targeting function comprises a central control module, a light stimulation module, an optical fiber, a signal acquisition module and a slow release module, wherein the central control module controls the light stimulation module, the signal acquisition module and the slow release module; the slow release module is used for releasing the targeted light sensitive material and/or the light sensitive gene; the optical stimulation module generates laser and performs optical stimulation on the targeted photosensitive material and/or photosensitive gene through the optical fiber; the signal acquisition module is used for acquiring biological signals in a focus area before and after light stimulation and sending the biological signals to the central control module, the central control module analyzes and processes the biological signals to generate corresponding parameters, and the light stimulation module and the slow release module are respectively controlled according to the parameters.
Preferably, the light stimulation module includes a first light source, a second light source and a third light source, the first light source excites the targeted light sensing material through the optical fiber, and the second light source and the third light source excite the light sensitive gene through the optical fiber.
Preferably, the first light source generates ultraviolet light with a wavelength range of 300-400 nanometers.
Preferably, the second light source generates blue light having a wavelength of 473 nm and the third light source generates yellow light having a wavelength of 594 nm.
Preferably, the targeted light sensation material includes one or both of an active targeted light sensation material and a passive targeted light sensation material.
Preferably, the active targeting light sensation material comprises a surface-modified, antibody-mediated or receptor-mediated photosensitizing agent.
Preferably, the passive targeting photosensitive material comprises one or more than two of nano titanium dioxide, nano zinc oxide, carbon nano tubes, graphene, fullerene and organic photoelectric materials.
Preferably, the size of the passive targeted photo sensation material is less than 100 nanometers.
Preferably, the sustained release module is also used for releasing one or two of neurotrophic factors and blood vessel growth factors.
Preferably, the signal acquisition module comprises one or more than two of an electric signal acquisition unit, an optical signal acquisition unit, a chemical sensor and a biological sensor.
Preferably, the biological signal comprises one or more of electrophysiological signal, optical signal, temperature, pH value, blood glucose concentration, oxygen concentration, ion concentration.
Preferably, the therapeutic device with the targeting function further comprises an electrical stimulation device and an electrode, the central control module controls the electrical stimulation device, and the electrical stimulation device performs electrical stimulation through the electrode.
Preferably, the treatment device with the targeting function further comprises a power supply module, and the power supply module is used for supplying electric energy to the central control module, the light stimulation module, the signal acquisition module and the slow release module.
Preferably, the power module is one or more of a primary battery, a secondary battery and a radio frequency power supply module.
According to the treatment device with the targeting function, the sustained-release module is adopted to release the targeted light sensation material to the tumor cells, the light stimulation module generates laser to excite the targeted light sensation material to kill the tumor cells, the targeted light sensation material can accurately enter the tumor cells but not the normal cells, and when the targeted light sensation material is excited by the laser, the damage to the normal tissues of a patient can be reduced, and the treatment effect is improved.
[ description of the drawings ]
FIG. 1 is a schematic structural view of a therapeutic device having a targeting function in one embodiment;
fig. 2 is a schematic structural diagram of a therapeutic device having a targeting function in another embodiment.
[ detailed description ] embodiments
The following detailed description is given in conjunction with specific examples.
As shown in fig. 1, in one embodiment, a therapeutic device with a targeting function includes a central control module 10, a sustained release module 20, a signal acquisition module 30, a light stimulation module 40, and an optical fiber 50. Wherein,
the central control module 10 controls the slow release module 20, the signal acquisition module 30 and the light stimulation module 40 to work.
The slow release module 20 is used for releasing the targeted photosensitive material and/or photosensitive gene. The targeted light sensitive material is used for selectively entering tumor cells and is excited under the irradiation of laser to kill the tumor cells; the photosensitive gene is used for being excited under laser irradiation to regulate and control target cells, and plays roles in inhibiting tumor growth and helping nerve function reconstruction. The targeted light sensation material comprises one or two of an active targeted light sensation material and a passive targeted light sensation material, wherein the active targeted light sensation material comprises a photosensitive preparation which is chemically or biologically modified; the passive targeting light sensation material comprises one or more than two of nano titanium dioxide, nano zinc oxide, carbon nano tubes, graphene, fullerene and organic photoelectric materials, and the size of the passive targeting light sensation material is less than 100 nanometers. Because the permeability of the capillary vessels of the tumor tissue is greater than that of the normal tissue, the nano particles below 100 nanometers can easily permeate into the tumor tissue through the capillary vessel wall of the focus part, and the capillary vessels of the normal tissue have small permeability and are not allowed to pass, so that the material with the size less than 100 nanometers can passively diffuse into the tumor cells, and more accurate positioning is realized.
In addition, the sustained release module 20 is also used for releasing one or two drugs of neurotrophic factors and blood vessel growth factors. Neurotrophic factors and angiogenic factors are used to promote nerve and vascular regeneration at the site of the lesion.
The signal collecting module 30 is used for collecting the biological signals in the focal zone before and after the light stimulation and sending the biological signals to the central control module 10. The signal collecting module 30 includes one or more of an electrical signal collecting unit, an optical signal collecting unit, a chemical sensor, and a biosensor. The biological signal comprises one or more of electrophysiological signal, optical signal, temperature, pH, blood glucose concentration, oxygen concentration, and ion concentration. The electric signal acquisition unit is used for acquiring electrophysiological signals and optical signals, the chemical sensor can be used for acquiring signals such as pH values, temperatures and ion concentrations, and the biosensor can be used for acquiring blood glucose concentration and oxygen concentration. The growth status of the tumor can be analyzed by collecting biological signals. Wherein, the electrophysiological signal is used for analyzing the nerve activity condition of the focus part; the optical signal is used for observing the activity condition of the target cell of the introduced photosensitive gene; the temperature can determine the information of the position, the size and the like of the tumor, and the temperature of the tumor tissue is generally higher than that of the normal tissue; the pH value can reflect the growth condition of the tumor tissue, and the pH value of the tumor interstitial fluid is obviously lower than that of the surrounding normal tissue; the blood sugar concentration or the oxygen concentration can indirectly reflect the activity of tumor tissues, and the tumor cells are in a hypoxic state for a long time due to vigorous metabolism and high diffusion speed; the specific ion concentration can reflect the growth condition of tumor tissues, and because tumor blood vessels grow rapidly, the growth condition usually causes the deficiency of adventitial cells, the deformation of basement membrane and the defect of lymphatic return system.
The signal collection module 30 sends the collected biological signals to the central control module 10, and the central control module 10 can analyze and process the biological signals to generate corresponding parameters, and then respectively control the slow release module 10 and the light stimulation module 40 according to the parameters. Parameters include, among others, frequency of stimulation (in hertz), intensity (in volts or amperes), duration (in seconds), interval (in seconds), flow rate (in milliliters per second, mL/s), and the like. The central control module 10 can also feed back the information of the biological signals to a connected computer, and output the information of the biological signals in forms of tables, images or sounds, so that doctors or patients can know the information in time.
The optical stimulation module 40 includes a first light source, a second light source, and a third light source. The first light source is used for generating laser and exciting the targeted photosensitive material through the optical fiber 50, and the second light source and the third light source are used for generating laser and exciting the photosensitive gene through the optical fiber 50. Wherein the first light source generates ultraviolet light with a wavelength range of 300-400 nanometers (nm); the second light source generates blue light with the wavelength of 473 nanometers; the third light source generates yellow light with a wavelength of 594 nm. The laser generated by the optical stimulation module 40 penetrates into the target tissue through the optical fiber 50 to irradiate, the laser generated by the first light source excites the targeted light sensation material to act and kill the tumor cells, other normal tissues are not affected, and due to the special property of the combination of the targeted light sensation material and the target cells, the passive targeted light sensation material can be continuously diffused into other tumor cells after the tumor cells are killed, so that the requirement of treatment can be met with a small dosage.
After the tumor cells are killed, the photosensitive gene can be transferred into neurons through a specific promoter and expressed. Blue (472 nm wavelength) or yellow (593 nm wavelength) laser light from the third laser is emitted by the second laser and is irradiated into the target tissue by the optical fiber 50. Since blue or yellow laser light acts only on cells into which a photosensitivity gene has been introduced, it has very strong cell specificity and can effectively excite or inhibit neurons. Wherein, the excitatory channel protein gene is ChR2(Channelrhodopsin-2), and the inhibitory channel protein gene is NpHR (Helorhodopsin). The light stimulation module 40 provides light stimulation to neurons with light sensitive genes in the brain through the optical fibers 50 embedded in the brain, thereby causing excitation or inhibition of the neurons, i.e., the neurons expressing excitatory channel protein genes are stimulated by blue light, so that the neurons are excited; and stimulating the neurons expressing the inhibitory channel protein genes with yellow light will inhibit the neurons. The nerve circuit can be regulated and controlled through excitation or inhibition, thereby achieving the purposes of treating damaged nerve tissues and remodeling nerve functions.
In one embodiment, as shown in fig. 2, the therapeutic device with targeting function further includes an electrical stimulation module 60, an electrode 70 and a power supply module (not shown) in addition to the central control module 10, the slow release module 20, the signal acquisition module 30, the optical stimulation module 40 and the optical fiber 50. The central control module 10 controls the electrical stimulation module 60 to perform electrical stimulation through the electrodes 70. The electrical stimulation module 60 is to implant an electrode 70 at a specific position in the brain by utilizing brain stereotactic surgery, stimulate the deep nerve nuclei of the brain by generating current or potential pulses, and the central control module 10 can adjust the current intensity and the potential pulse frequency to achieve the effect of killing tumor cells. The electrical stimulation therapy generated by the electrical stimulation module 60 may be complementary to the light stimulation therapy. In addition, the electrode 70 and the optical fiber 50 may be integrated.
The power module provides electric energy for the central control module 10, the slow release module 20, the signal acquisition module 30, the light stimulation module 40, the electrical stimulation module 60 and the electrode 70. The power module 80 may be one or more of a primary battery, a secondary battery, and a radio frequency power supply module. Wherein, the primary battery can be a lithium battery, a silver oxide battery or a biological fuel battery (such as glucose catalyzed by enzyme to provide electric energy); the secondary battery may be a lithium ion battery or a lithium polymer battery. The radio frequency power supply module generates electric energy by induction through a coil implanted in the living body. For more stable and durable power supply, both the rf power supply module and the biofuel cell may be used together with a secondary battery to charge it.
The working process of the treatment device with the targeting function is as follows: the central control module 10 controls the slow release module 20 to release the targeted light sensitive material and the light sensitive gene, the first laser of the light stimulation module 40 generates 300-400 nm ultraviolet light to excite the targeted light sensitive material to act in the tumor cells to kill the tumor cells, the signal acquisition module 20 acquires biological signals and sends the biological signals to the central control module 10, the central control module 10 analyzes and processes the acquired biological signals to generate corresponding parameters, the light stimulation module 40 is adjusted through the parameters to further kill the tumor cells, the second laser and the third laser of the light stimulation module 40 respectively generate blue light and yellow light sensitive exciting light genes to be expressed in target cells, and therefore the purposes of treating nerve tissues and remodeling nerve functions are achieved.
According to the treatment device with the targeting function, the sustained-release module 20 is adopted to release the targeted light sensation material into the tumor cells, the light stimulation module 40 generates laser to excite the targeted light sensation material to kill the tumor cells, and the targeted light sensation material can accurately enter the tumor cells but not the normal cells, so that when the targeted light sensation material is excited by the laser, the damage to the normal tissues of a patient can be reduced, and the treatment effect is improved.
In addition, the slow release module 20 is adopted to release the photosensitive gene to the nerve tissue, and the light stimulation module 40 generates laser to excite the photosensitive gene to express, so that the nerve tissue is repaired, and the damage to the normal tissue is reduced; the sustained release module 20 can also release neurotrophic factors to promote the growth and activity of nerves, or release blood vessel growth factors to enhance the microcirculation of the focus area and promote the repair of focus tissues, thereby promoting the repair of normal tissues; the passive targeting light sensation material is adopted, so that the material can be recycled, the adverse effect of the medicine on the human body is reduced, and the treatment cost is saved; the electrical stimulation module 60 and the electrode 70 are adopted to realize electrical stimulation treatment as an auxiliary means of optical stimulation treatment, so that the treatment effect is improved.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (14)
1. A therapeutic device having a targeting function, characterized in that: the device comprises a central control module, a light stimulation module, an optical fiber, a signal acquisition module and a slow release module, wherein the central control module controls the light stimulation module, the signal acquisition module and the slow release module; the slow release module is used for releasing the targeted light sensitive material and/or the light sensitive gene; the optical stimulation module generates laser and performs optical stimulation on the targeted photosensitive material and/or photosensitive gene through the optical fiber; the signal acquisition module is used for acquiring biological signals in a focus area before and after light stimulation and sending the biological signals to the central control module, the central control module analyzes and processes the biological signals to generate corresponding parameters, and the light stimulation module and the slow release module are respectively controlled according to the parameters.
2. The treatment device with targeting function according to claim 1, characterized in that: the light stimulation module comprises a first light source device, a second light source device and a third light source device, the first light source device excites the targeted light sensation material through the optical fibers, and the second light source device and the third light source device excite the light sensitivity genes through the optical fibers.
3. The treatment device with targeting function according to claim 2, characterized in that: the first light source generates ultraviolet light with the wavelength range of 300-400 nanometers.
4. The treatment device with targeting function according to claim 2, characterized in that: the second light source generates blue light having a wavelength of 473 nm and the third light source generates yellow light having a wavelength of 594 nm.
5. The treatment device with targeting function according to claim 1, characterized in that: the targeted light sensation material comprises one or two of an active targeted light sensation material and a passive targeted light sensation material.
6. The treatment device with targeting function according to claim 5, characterized in that: the active targeting photosensitive material comprises a photosensitive preparation subjected to surface modification, antibody mediation or receptor mediation.
7. The treatment device with targeting function according to claim 5, characterized in that: the passive targeting light sensation material comprises one or more than two of nano titanium dioxide, nano zinc oxide, a carbon nano tube, graphene, fullerene and an organic photoelectric material.
8. The treatment device with targeting function according to claim 5, characterized in that: the size of the passive targeted light sensation material is less than 100 nanometers.
9. The treatment device with targeting function according to claim 1, characterized in that: the slow release module is also used for releasing one or two of neurotrophic factors and blood vessel growth factors.
10. The treatment device with targeting function according to claim 1, characterized in that: the signal acquisition module comprises one or more than two of an electric signal acquisition unit, an optical signal acquisition unit, a chemical sensor and a biological sensor.
11. The treatment device with targeting function according to claim 1, characterized in that: the biological signal comprises one or more than two of electrophysiological signal, optical signal, temperature, pH value, blood glucose concentration, oxygen concentration and ion concentration.
12. The treatment device with targeting function according to claim 1, characterized in that: the treatment device with the targeting function further comprises an electrical stimulation device and an electrode, the central control module controls the electrical stimulation device, and the electrical stimulation device carries out electrical stimulation through the electrode.
13. The treatment device with targeting function according to claim 1, characterized in that: the treatment device with the targeting function further comprises a power supply module, and the power supply module is used for providing electric energy for the central control module, the light stimulation module, the signal acquisition module and the slow release module.
14. The targeted therapeutic device of claim 13, wherein: the power supply module is one or more than two of a primary battery, a secondary battery and a radio frequency power supply module.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010557946 CN102039007A (en) | 2010-11-24 | 2010-11-24 | Therapy equipment with targeting function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010557946 CN102039007A (en) | 2010-11-24 | 2010-11-24 | Therapy equipment with targeting function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102039007A true CN102039007A (en) | 2011-05-04 |
Family
ID=43905757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010557946 Pending CN102039007A (en) | 2010-11-24 | 2010-11-24 | Therapy equipment with targeting function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102039007A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102277297A (en) * | 2011-08-16 | 2011-12-14 | 中国科学院深圳先进技术研究院 | Implanted in vivo electrotransfection device |
| CN102764481A (en) * | 2012-07-13 | 2012-11-07 | 中国科学院深圳先进技术研究院 | Photostimulation device and method for adjusting photostimulation temperature |
| CN107789743A (en) * | 2016-08-31 | 2018-03-13 | 北京至感传感器技术研究院有限公司 | Noninvasive therapeutic apparatus for treating tumor |
| CN109621223A (en) * | 2019-01-30 | 2019-04-16 | 广东工业大学 | A kind of light stimulus system |
| CN114849060A (en) * | 2022-05-07 | 2022-08-05 | 江苏省人民医院（南京医科大学第一附属医院） | Application of electrical stimulation in regulating and controlling MDK in organism |
| CN115634071A (en) * | 2021-07-20 | 2023-01-24 | 中国科学院深圳先进技术研究院 | Signal processing system |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209349A (en) * | 2006-12-27 | 2008-07-02 | 中国科学院大连化学物理研究所 | Application of carbon nano-tube as carrier in transferring anti-cancer medicine |
| CN101269257A (en) * | 2007-03-20 | 2008-09-24 | 深圳市微创医学科技有限公司 | Optical power therapentic equipment |
| CN101569778A (en) * | 2009-03-10 | 2009-11-04 | 深圳先进技术研究院 | Biofeedback simulation system and biofeedback simulation method |
-
2010
- 2010-11-24 CN CN 201010557946 patent/CN102039007A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209349A (en) * | 2006-12-27 | 2008-07-02 | 中国科学院大连化学物理研究所 | Application of carbon nano-tube as carrier in transferring anti-cancer medicine |
| CN101269257A (en) * | 2007-03-20 | 2008-09-24 | 深圳市微创医学科技有限公司 | Optical power therapentic equipment |
| CN101569778A (en) * | 2009-03-10 | 2009-11-04 | 深圳先进技术研究院 | Biofeedback simulation system and biofeedback simulation method |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102277297A (en) * | 2011-08-16 | 2011-12-14 | 中国科学院深圳先进技术研究院 | Implanted in vivo electrotransfection device |
| CN102277297B (en) * | 2011-08-16 | 2013-06-05 | 中国科学院深圳先进技术研究院 | Implanted in vivo electrotransfection device |
| CN102764481A (en) * | 2012-07-13 | 2012-11-07 | 中国科学院深圳先进技术研究院 | Photostimulation device and method for adjusting photostimulation temperature |
| CN102764481B (en) * | 2012-07-13 | 2015-04-15 | 中国科学院深圳先进技术研究院 | Photostimulation device and method for adjusting photostimulation temperature |
| CN107789743A (en) * | 2016-08-31 | 2018-03-13 | 北京至感传感器技术研究院有限公司 | Noninvasive therapeutic apparatus for treating tumor |
| CN109621223A (en) * | 2019-01-30 | 2019-04-16 | 广东工业大学 | A kind of light stimulus system |
| CN115634071A (en) * | 2021-07-20 | 2023-01-24 | 中国科学院深圳先进技术研究院 | Signal processing system |
| CN114849060A (en) * | 2022-05-07 | 2022-08-05 | 江苏省人民医院（南京医科大学第一附属医院） | Application of electrical stimulation in regulating and controlling MDK in organism |
| CN114849060B (en) * | 2022-05-07 | 2023-08-25 | 江苏省人民医院（南京医科大学第一附属医院） | Application of electric stimulation in regulation and control of MDK in organism |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| All et al. | Expanding the toolbox of upconversion nanoparticles for in vivo optogenetics and neuromodulation | |
| Lin et al. | Core–shell–shell upconversion nanoparticles with enhanced emission for wireless optogenetic inhibition | |
| C Thompson et al. | Optical stimulation of neurons | |
| CN102019040B (en) | Biofeedback photoelectric therapeutic device | |
| CN102039007A (en) | Therapy equipment with targeting function | |
| Liu et al. | Review of noninvasive or minimally invasive deep brain stimulation | |
| US20130046357A1 (en) | Tissue or nerve treatment device and method | |
| CN104645331A (en) | Drug-loading micro-needle promoted and controlled by nanogold photo-thermal effect | |
| CN105682738B (en) | For controlling the device of laser microprobe | |
| CN101485920B (en) | Laser therapy device | |
| Wang et al. | Ultrasound-Induced Cascade Amplification in a Mechanoluminescent Nanotransducer for Enhanced Sono-Optogenetic Deep Brain Stimulation | |
| CN101862510B (en) | Two-photon excitation based tumor diagnosis and photodynamic tumor-treatment instrument | |
| CN101485917B (en) | System for treating epilepsy | |
| Mou et al. | Gold nanorod-assisted near-infrared stimulation of bullfrog sciatic nerve | |
| Yu et al. | Intrinsic cell-type selectivity and inter-neuronal connectivity alteration by transcranial focused ultrasound | |
| CN115006730B (en) | Dual-channel optogenetic method, rare earth-based near infrared nanomaterial system and application thereof | |
| Coventry et al. | Short-wave infrared neural stimulation drives graded sciatic nerve activation across a continuum of wavelengths | |
| WO2021108674A9 (en) | Modulating photosensitive proteins with mechanoluminescent particles | |
| CN112451862A (en) | Photodynamic therapy system and control method thereof | |
| CN112654392A (en) | Neuromodulation techniques | |
| RU2723884C2 (en) | Method of initiating the death of tumor cells with sodium chloride chlorine-e6, succinic acid and hf and shf wave radiation energy | |
| Wells et al. | Frontiers in optical stimulation of neural tissues: past, present, and future | |
| RU2724326C2 (en) | Method for initiating the death of tumor cells with sodium salts of chlorine-e6, chlorine-p6 and purpurin-5 and hf and microwave radiation with wave radiation energy | |
| WO2008153443A1 (en) | Method for bio-controllable photo-dynamic therapy | |
| RU2726608C2 (en) | Method for initiation of tumor cell death by sodium salt of hematoporbore and hf and shf wave energy radiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110504 |